Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an update.
PYC Therapeutics Limited has released its 2025 Annual Report, highlighting its strategic initiatives and financial performance. The report underscores the company’s commitment to advancing its therapeutic pipeline, which could enhance its position in the biotechnology industry and potentially benefit stakeholders through improved market competitiveness.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a biotechnology company listed on the Australian Securities Exchange. It is based in Western Australia and focuses on developing innovative therapeutic solutions.
Average Trading Volume: 635,828
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$758.2M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.